8-K: Senti Bio Announces Positive Initial Clinical Data for SENTI-202 CAR-NK Cell Therapy in AML Trial

Senti Biosciences reports promising early results from a Phase 1 trial of SENTI-202, with two out of three AML patients achieving complete remission and MRD negativity at the first dose level.

Summary

• Senti Biosciences has released initial clinical data from a Phase 1 trial of SENTI-202, a CAR-NK cell therapy for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML).
• Three AML patients were treated at the lowest dose level of 1.0 billion CAR+ NK cells per dose.
• As of the data cutoff date of September 19, 2024, two of the three patients achieved complete remission (CR), confirmed by bone marrow biopsy.
• Both patients who achieved CR were also assessed as measurable residual disease (MRD) negative.
• The remissions have been maintained for 4+ months and 3+ months, respectively, as of the report date.
• SENTI-202 was generally well-tolerated, with an adverse event profile consistent with lymphodepleting chemotherapy in AML patients.
• The trial is continuing with dose escalation, and additional response and durability data are expected in 2025.
• The company plans to enroll approximately 20 patients in the Phase 1 trial.

Sentiment

Score: 8

Explanation: The document presents very positive initial clinical data with a high rate of complete remission and MRD negativity, suggesting a promising therapy. The safety profile is also encouraging. However, it is still early data from a small sample size, so there is some caution.

Positives

• The initial clinical data for SENTI-202 shows a high rate of complete remission (CR) at the first dose level.
• The therapy demonstrated a good safety profile, with no dose-limiting toxicities observed.
• The patients who achieved CR also achieved MRD negativity, indicating a deep response.
• The remissions have been maintained for several months, suggesting potential durability.
• The company is actively enrolling patients in a higher dose cohort.

Negatives

• One patient did not respond to the treatment and was refractory to therapy.
• The adverse event profile was consistent with lymphodepleting chemotherapy, which can have side effects.
• The data is from a small sample size of three patients at the first dose level.

Risks

• The results are based on a small number of patients and may not be representative of the broader patient population.
• The long-term durability of the remissions is not yet known.
• The trial is still in the early stages, and further data is needed to confirm the efficacy and safety of SENTI-202.
• There are risks associated with clinical trial start up, patient enrollment, and GMP manufacturing activities.
• The company is dependent on third parties for clinical trial and manufacturing activities.

Future Outlook

The company expects to enroll a total of approximately 20 patients in the Phase 1 trial and anticipates additional safety and efficacy data, including initial durability data, in 2025.

Management Comments

• Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio, stated that the early and deep responses at the first dose level, along with a well-tolerated safety profile, are very encouraging.
• Stephen A. Strickland, Jr., MD, MSCI, Director, Leukemia Research for Sarah Cannon Research Institute, expressed encouragement by the initial findings and suggested that SENTI-202 may address the limitations of existing therapies for AML.

Industry Context

The announcement is significant in the context of the broader cell therapy field, particularly for CAR-NK therapies, which are being explored as a potential alternative to CAR-T therapies. The positive initial results for SENTI-202 could position Senti Bio as a leader in this space, especially given the focus on off-the-shelf therapies for AML, a disease with limited treatment options.

Comparison to Industry Standards

• The results of 2 out of 3 patients achieving complete remission (CR) and MRD negativity at the first dose level are promising compared to standard treatments for relapsed/refractory AML, which often have lower response rates and significant toxicities.
• While direct comparisons to other CAR-NK therapies are difficult due to varying trial designs and patient populations, the early data suggests that SENTI-202 is showing competitive efficacy and a favorable safety profile.
• Companies like Fate Therapeutics and Nkarta are also developing allogeneic NK cell therapies, and the results from Senti Bio will be closely watched by investors and competitors.
• The use of a logic-gated approach with an OR gate and a NOT gate is a novel approach that could differentiate SENTI-202 from other CAR-NK therapies.

Stakeholder Impact

• Shareholders may react positively to the promising initial clinical data.
• Patients with relapsed/refractory AML may have a new potential treatment option.
• Employees of Senti Bio may be motivated by the positive results.
• The results may attract potential partners and investors.

Next Steps

• The company will continue dose escalation in the Phase 1 trial.
• The company expects to enroll a total of approximately 20 patients in the Phase 1 trial.
• Additional safety and efficacy data, including initial durability data, are expected in 2025.

Key Dates

Keywords

SENTI-202, CAR-NK cell therapy, Acute Myeloid Leukemia, AML, Hematologic Malignancies, Clinical Trial, Complete Remission, MRD Negative, Cell Therapy, Senti Bio